RedShift BioAnalytics Announces Launch of Next Generation Apollo for Ultra-Sensitive Biophysical Characterization of Biomolecules
RedShift BioAnalytics (RedShiftBio?) announces the launch of Apollo, the company’s latest system using ground-breaking MMS technology. Apollo provides ultra-sensitive, ultra-precise measurements of the structure of biomolecules through a novel technology called Microfluidic Modulation Spectroscopy (MMS), now even more rapidly, with less sample volume, with improved software analytics features.
MMS overcomes many of the limitations of existing technologies in a typical biophysical characterization toolkit with ultra-sensitive highly reproducible structural measurements of proteins other biomolecules. Users are able to compare higher-order structure similarity profiles for confidence in structural similarity activity to inform discovery, screening, formulation, quality control in biopharmaceutical drug development. It can be used for a wide range of biomolecules from mAb-based biotherapeutics to robust measurements of ADCs, AAVs, mRNA.
Key features benefits of Apollo include:
- Accurate reproducible measurements with broad concentration range from 0.1 mg/ml to >200 mg/ml allows measurements in native conditions
- 20x faster 30x more sensitive to changes in structure than CD or FTIR
- Real-time buffer subtraction minimizes background noise interference from excipients
- Dramatically reduced sample volume requirements from first-generation AQS3pro
“Apollo represents a tremendous step forward in our product portfolio, incorporating the feedback from our customers at leading biopharmaceutical companies in North America, Europe, Asia,” said Julien Bradley, CEO of RedShiftBio. “The improvements over our first generation AQS3pro system are very significant will make our already industry-leading tool in biophysical characterization even more valuable easy to use in a wider range of applications.”